Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept

Frederick Hausheer, Stacey Bain, Michael Perry, Lingu Du, Yasuo Ohashi, Yutaka Ariyoshi, Masahiro Fukuolca

Research output: Contribution to journalArticle

Abstract

We performed a comprehensive meta-analysis of two recent, multicenter, randomized, and controlled trials of the investigational new drug Tavocept (vs. placebo or no Tavocept) in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) who were treated with taxane plus cisplatin therapy. Significant improvements in overall and l-year survival were observed, which were most apparent in patients with the adenocarcinoma subtype. The results of this meta-analysis support the view that Tavocept combined with taxane plus cisplatin first-line therapy may result in significant increases in overall and i-year survival in patients with primary adenocarcinoma of the lung. The results of this systematic meta-analysis were used for the design and scientific justification of an international, double-blind, and placebo-controlled phase III confirmatory trial of Tavocept in patients with advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with taxane plus cisplatin using a primary endpoint of overall survival.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalAsia-Pacific Journal of Oncology and Hematology
Volume2
Issue number1
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Multicenter Studies
Meta-Analysis
Cisplatin
Survival
Placebos
Investigational Drugs
Adenocarcinoma
Randomized Controlled Trials
Drug Therapy
2,2'-dithiodiethanesulfonic acid
Therapeutics
taxane
Adenocarcinoma of lung

Keywords

  • Adenocarcinoma
  • Antitumor enhancement
  • BNP7787
  • Chemoprotection
  • Lung cancer
  • Meta-analysis
  • Survival
  • Tavocept

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept. / Hausheer, Frederick; Bain, Stacey; Perry, Michael; Du, Lingu; Ohashi, Yasuo; Ariyoshi, Yutaka; Fukuolca, Masahiro.

In: Asia-Pacific Journal of Oncology and Hematology, Vol. 2, No. 1, 02.2010, p. 1-13.

Research output: Contribution to journalArticle

@article{f8bb4ef4ebd747429504e4896fc8b5e3,
title = "Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept",
abstract = "We performed a comprehensive meta-analysis of two recent, multicenter, randomized, and controlled trials of the investigational new drug Tavocept (vs. placebo or no Tavocept) in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) who were treated with taxane plus cisplatin therapy. Significant improvements in overall and l-year survival were observed, which were most apparent in patients with the adenocarcinoma subtype. The results of this meta-analysis support the view that Tavocept combined with taxane plus cisplatin first-line therapy may result in significant increases in overall and i-year survival in patients with primary adenocarcinoma of the lung. The results of this systematic meta-analysis were used for the design and scientific justification of an international, double-blind, and placebo-controlled phase III confirmatory trial of Tavocept in patients with advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with taxane plus cisplatin using a primary endpoint of overall survival.",
keywords = "Adenocarcinoma, Antitumor enhancement, BNP7787, Chemoprotection, Lung cancer, Meta-analysis, Survival, Tavocept",
author = "Frederick Hausheer and Stacey Bain and Michael Perry and Lingu Du and Yasuo Ohashi and Yutaka Ariyoshi and Masahiro Fukuolca",
year = "2010",
month = "2",
language = "English (US)",
volume = "2",
pages = "1--13",
journal = "Asia-Pacific Journal of Oncology and Hematology",
issn = "1759-6637",
publisher = "San Lucas Medical",
number = "1",

}

TY - JOUR

T1 - Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept

AU - Hausheer, Frederick

AU - Bain, Stacey

AU - Perry, Michael

AU - Du, Lingu

AU - Ohashi, Yasuo

AU - Ariyoshi, Yutaka

AU - Fukuolca, Masahiro

PY - 2010/2

Y1 - 2010/2

N2 - We performed a comprehensive meta-analysis of two recent, multicenter, randomized, and controlled trials of the investigational new drug Tavocept (vs. placebo or no Tavocept) in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) who were treated with taxane plus cisplatin therapy. Significant improvements in overall and l-year survival were observed, which were most apparent in patients with the adenocarcinoma subtype. The results of this meta-analysis support the view that Tavocept combined with taxane plus cisplatin first-line therapy may result in significant increases in overall and i-year survival in patients with primary adenocarcinoma of the lung. The results of this systematic meta-analysis were used for the design and scientific justification of an international, double-blind, and placebo-controlled phase III confirmatory trial of Tavocept in patients with advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with taxane plus cisplatin using a primary endpoint of overall survival.

AB - We performed a comprehensive meta-analysis of two recent, multicenter, randomized, and controlled trials of the investigational new drug Tavocept (vs. placebo or no Tavocept) in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) who were treated with taxane plus cisplatin therapy. Significant improvements in overall and l-year survival were observed, which were most apparent in patients with the adenocarcinoma subtype. The results of this meta-analysis support the view that Tavocept combined with taxane plus cisplatin first-line therapy may result in significant increases in overall and i-year survival in patients with primary adenocarcinoma of the lung. The results of this systematic meta-analysis were used for the design and scientific justification of an international, double-blind, and placebo-controlled phase III confirmatory trial of Tavocept in patients with advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with taxane plus cisplatin using a primary endpoint of overall survival.

KW - Adenocarcinoma

KW - Antitumor enhancement

KW - BNP7787

KW - Chemoprotection

KW - Lung cancer

KW - Meta-analysis

KW - Survival

KW - Tavocept

UR - http://www.scopus.com/inward/record.url?scp=77956584095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956584095&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77956584095

VL - 2

SP - 1

EP - 13

JO - Asia-Pacific Journal of Oncology and Hematology

JF - Asia-Pacific Journal of Oncology and Hematology

SN - 1759-6637

IS - 1

ER -